Eli Lilly Earns Landmark Approval for Alzheimer's Disease Imaging Agent
On Thursday, the Food and Drug Administration (FDA) approved the use of a radioactive diagnostic instrument for patients under evaluation for Alzheimer's disease. This drug from Eli Lilly (NYSE: LLY) is the first that the FDA has approved to look for tau neurofibrillary tangles (NFTs) in the brain.
The number of Americans living with Alzheimer's disease is expected to rise from around 5 million in 2014 to around 14 million by 2060. There are no treatments proven to slow the progression of this ultimately fatal disease yet, but a better understanding of NFTs and their association with dementia could go a long way to help.
Image source: Getty Images.
Source Fool.com
